4Takahaski K,Ouygan X,Komatsu K,et al .Sodium tanshinone Ⅱ A sulfonate derived from danshen(salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin Ⅱ in cultured neonated rat cardiac cells[J].Biochem Pharmacot, 2002, 64(4):745-749.
1Murray CJL, Lopez AD. Evidence-based health policy -lessons from the Global Burden of Disease Study. Science, 1996; 274: 740～ 743
2Murray CJL, Lopez, eds. The global burden of disease: Acomprehensive assessment of mortality and disability from diseases, injury and risk factors in 1990 and projected to 2020. Cambridge, MA.:Harvard University Press, 1996
3World Development Indicators Database, Worldbank, 2001
4Siafakas NM, Vemeire P, Pride NB, et al. ERS Consensus Statement. Optimal assessment and management of chronic obstructive puhnonary disease (COPD). Eur Respir J, 1995; 8:1398～1420
5ATS statement. Standrads for the diagnosis and care of patients with chronic obstructive puhmonary disease. Am J Respir Crit Care Med, 1995; 152: S77～ S120
6Guidelines for the management of chronic obstructive pulmonary disease. Tbe Thoracic Society of Australia and New Zealand. Modern Medicine of Australia,July 1995; 138:7:132～146
7The COPD guidelines Group of the standards of care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax, 1997; 52: S1～S28
8Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO report . NIH,NHLBI publication, Number 2701, April 2001
9Tan WC, Seale P, Charoenratanakul S, et al. Chronic obstructive puhmonary disease (COPD) prevalence in 12 Asian countries: projections based on the COPD Prevalence Estimation Model. Poster presented at the American Thoracic Society Meeting, May 2001,San Francisco, USA
10Schau BS, Lopez-Vidriero M,Peabody J,et al. Chronic Obstructive Pulmonary Disease: A Prevalence Estimation Model. Am J Resp Crit Care Med,2000; 16:A799
